A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Czechia- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Zdravotniku 248/7, 779 00 Olomouc, Czechia
University Hospital Olomouc in Olomouc, Czechia specialises in clinical trials of conditions such as Non-small cell lung cancer, Plasma cell myeloma, Squamous cell carcinoma of head and neck, Hormone-refractory prostate cancer, and other specialisations. This site conducts important research.
The University Hospital Olomouc is active in nephrology and oncology, with studies focused on kidney-related diseases and renal cell carcinoma. This research is mainly aimed at testing new treatment approaches, comparing them with standard care, and improving outcomes for people with advanced kidney disease and kidney cancer.
Work at this site also includes studies on kidney cancer recurrence prevention and better control of proteinuria and renal function in chronic kidney disorders.
Research in respiratory diseases at University Hospital Olomouc covers both common and complex lung conditions. The trials are designed to evaluate new therapies, reduce symptoms, and improve breathing capacity and long-term disease control in patients with difficult-to-treat pulmonary disorders.
These studies reflect a strong focus on lung function, inflammation, and treatment effectiveness in chronic respiratory disease.
The site conducts broad cancer research spanning solid tumors and hematologic malignancies. Many trials aim to improve survival, delay disease progression, and refine treatment choices for patients with advanced or hard-to-treat cancers.
Research here includes studies of immunotherapy, targeted therapy, and combination treatment strategies to better manage advanced malignancies.
Clinical trials in urologic oncology at this hospital focus on prostate and bladder cancers, with an emphasis on improving disease control and reducing the risk of progression or recurrence. The goal is to evaluate whether newer treatments can offer better outcomes than current standard approaches.
These studies highlight the use of precision imaging and advanced cancer therapies in men’s health and urinary tract cancers.
The research portfolio also includes immune system diseases and transplant-related complications. Trials in this area are looking at safer and more effective ways to control inflammation, preserve organ function, and improve quality of life in chronic immune-driven conditions.
At University Hospital Olomouc, this work supports better management of autoimmune disease and post-transplant care through new therapeutic options.
Beyond cancer and kidney disease, the site is involved in trials across cardiovascular disease, digestive system disease, and women’s health. These studies are aimed at preventing major complications, easing symptoms, and improving day-to-day health in diverse patient groups.
This mix of studies shows a broad interest in preventive care, symptom relief, and treatment effectiveness across several internal medicine specialties.
The clinical trial program at this hospital also reaches into congenital and hereditary diseases. These studies are especially important for patients with rare conditions, where research is often needed to find more targeted and better tolerated treatment options.
Research in this field is focused on improving disease control, slowing progression, and expanding treatment possibilities for uncommon disorders.
Clinical trials currently enrolling participants at this site.
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
CzechiaMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.